(3) **Limitations.** For intramuscular or intravenous use only. Neomycin is not for use parenterally in food-producing animals because of prolonged residues in edible tissues. Labeling shall bear an appropriate expiration date. For use by or on the order of a licensed veterinarian.

§ 522.1503 Neostigmine methylsulfate injection.

(a) **Specifications.** Neostigmine methylsulfate injection contains two milligrams of neostigmine methylsulfate in each milliliter of sterile aqueous solution.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use.**

1. The drug is intended for use for treating rumen atony; initiating peristalsis which causes evacuation of the bowel; emptying the urinary bladder; and stimulating skeletal muscle contractions. It is a curare antagonist.

2. It is administered to cattle and horses at a dosage level of 1 milligram per 100 pounds of body weight subcutaneously. It is administered to sheep at a dosage level of 1 to 1 1/2 milligrams per 100 pounds body weight subcutaneously. It is administered to swine at a dosage level of 2 to 3 milligrams per 100 pounds body weight intramuscularly. These doses may be repeated as indicated.

3. The drug is contraindicated in mechanical, intestinal or urinary obstruction, late pregnancy, and in animals treated with other cholinesterase inhibitors.

4. Not for use in animals producing milk, since this use will result in contamination of the milk.

5. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1610 Olate sodium solution.

(a) **Specifications.** Each milliliter of sterile aqueous solution contains 50 milligrams of sodium olate.

(b) **Sponsor.** See No. 037990 in §510.600(c) of this chapter.

(c) **Conditions of use.—**

1. It is used in horses to stimulate infiltration of cellular blood components that subsequently differentiate into fibrous and/or fibrocartilagenous tissue.

2. The drug is administered by parenteral injection dependent upon the area of response desired. An injection of 1 milliliter will produce a response of approximately 15 square centimeters. Do not inject more than 2 milliliters per injection site. Regardless of the number of injection sites, the total volume used should not exceed 10 milliliters.


4. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1620 Orgotein for injection.

(a) **Specifications.** Orgotein for injection is packaged in a vial containing 5 milligrams of orgotein and 10 milligrams of sucrose as lyophilized sterile nonpyrogenic powder with directions for dissolving the contents of the vial in 2 milliliters of diluent which is sodium chloride injection, U.S.P.

(b) **Sponsor.** See No. 024991 in §510.600(c) of this chapter.

(c) **Conditions of use.—**

1. Horses. (i) It is used in the treatment of soft tissue inflammation associated with the musculoskeletal system.

   (ii) It is administered by deep intramuscular injection at a dosage level of 5 milligrams every other day for 2 weeks and twice weekly for 2 to 3 more weeks. Severe cases, both acute and chronic, may benefit more from daily therapy initially. Dosage may be continued beyond 5 weeks if satisfactory improvement has not been achieved.

   (iii) Not for use in horses intended for food.

2. Dogs. (i) It is used for the relief of inflammation associated with ankylosing spondylitis, spondylosis, and disc disease. When severe nerve damage is present, response will occur much more slowly, if at all.

   (ii) It is administered by subcutaneous injection at a dosage level of 5 milligrams every day for 6 days, and